Mac Well Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 20-06-2024
- Paid Up Capital ₹ 0.84 M
as on 20-06-2024
- Company Age 20 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.32 Cr
as on 20-06-2024
- Satisfied Charges ₹ 3.50 M
as on 20-06-2024
- Revenue 8.80%
(FY 2020)
- Profit -2.69%
(FY 2020)
- Ebitda 12.48%
(FY 2020)
- Net Worth 21.35%
(FY 2020)
- Total Assets 18.69%
(FY 2020)
About Mac Well Pharmaceuticals
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.84 M.
The company currently has active open charges totaling ₹2.32 Cr. The company has closed loans amounting to ₹3.50 M, as per Ministry of Corporate Affairs (MCA) records.
Sunil Kumar and Satpal Rana serve as directors at the Company.
- CIN/LLPIN
U24239DL2004PTC125382
- Company No.
125382
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Mar 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
West Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Mac Well Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunil Kumar  | Director | 12-Feb-2007 | Current |
| Satpal Rana | Director | 24-Mar-2004 | Current |
Financial Performance of Mac Well Pharmaceuticals.
Mac Well Pharmaceuticals Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 8.8% increase. The company also saw a slight decrease in profitability, with a 2.69% decrease in profit. The company's net worth Soared by an impressive increase of 21.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mac Well Pharmaceuticals?
In 2020, Mac Well Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 01 Mar 2023 | ₹1.30 Cr | Open |
Hdfc Bank Limited Creation Date: 07 Nov 2022 | ₹1.80 M | Open |
Hdfc Bank Limited Creation Date: 21 Jan 2022 | ₹2.10 M | Open |
How Many Employees Work at Mac Well Pharmaceuticals?
Mac Well Pharmaceuticals has a workforce of 24 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mac Well Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mac Well Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
